Physiomics launches revised WRAP retail offer alongside £490,000 placing

Physiomics ( (GB:PYC) ) has issued an announcement.

Physiomics plc has launched a revised retail equity offer via Winterflood’s Retail Access Platform to raise up to £110,000 by issuing as many as 27.5 million new shares at £0.004, matching the price of a concurrent £490,000 institutional placing. The fundraising, which follows the cancellation of a previous placing and retail offer, is aimed at giving existing UK retail shareholders the chance to participate on the same terms as institutional investors, with the new shares expected to be admitted to AIM around 20 March and ranking pari passu with existing stock.

Both the WRAP Retail Offer and the placing are conditional on admission of the new shares to trading on AIM, though the placing will proceed independently if the retail tranche does not complete. The move underlines Physiomics’ effort to diversify and deepen its investor base while securing fresh capital, but it also highlights the risks borne by small-cap investors, with the company stressing that shares are high risk, capital is at risk, and no prospectus will be published under UK public offer exemptions.

The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.44 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.

Spark’s Take on PYC Stock

According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.

To see Spark’s full report on PYC stock, click here.

More about Physiomics

Physiomics plc is a UK‑based mathematical modelling, data science and biostatistics specialist that supports biotech and pharmaceutical companies in developing new therapeutics and personalised medicine solutions. Leveraging proprietary computational tools, including its Virtual Tumour technology, the firm has contributed to more than 140 commercial drug development projects for clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.

Average Trading Volume: 7,523,612

Technical Sentiment Signal: Sell

Current Market Cap: £1.41M

Learn more about PYC stock on TipRanks’ Stock Analysis page.